Bryant E. Fong Profile


General Information


Name:	Bryant E. Fong
Company:	Burrill & Company
Title:	Principal of Burrill Investment Committee
Profile:	Mr. Fong joined Burrill & Company in 1998 and has been focused on sourcing, evaluating and investing in biotechnology companies through the Burrill Life Sciences Capital Funds, which combined total almost $1 billion for investments in the life sciences. During his almost 10-year tenure in the venture capital industry, Mr. Fong has developed an extensive network of venture capitalists, entrepreneurs, bankers, and consultants for sourcing deal flow. In addition, he works closely with local universities and their technology transfer offices to evaluate early-stage technologies for commercialization. He has been involved in over twenty-five venture capital financings including recent investments in Galapagos (GLPG), SCYNEXIS, Catalyst Biosciences, Alinea Pharmaceuticals, Pharmasset (VRUS), Elbion, Neurotech Pharmaceuticals, Logical Therapeutics, and TRF Pharma. Mr. Fong currently serves on the boards of directors for Neurotech Pharmaceuticals, TRF Pharma, Logical Therapeutics (observer), Elbion (observer), and Phytomedics (observer). Prior to joining Burrill & Company, Mr. Fong held positions as a biochemist and molecular biologist with two early stage biotechnology companies located in the San Francisco Bay Area. His first position involved working with eukaryotic recombinant expression systems and he was part of the first research group to publish on the expression of a four-gene system in S. cerevisiae in the production of recombinant human collagen. Later, Mr. Fong was hired as the first employee of Strata Biosciences to help develop and validate its high-throughput functional genomics platform. Mr. Fong